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1. Introduction
Total hip arthroplasty (THA) is an increasingly common and successful operation, with
76,759 procedures logged in the National Joint Registry for England and Wales in 2010 [1].
Overall satisfaction rates rank amongst the highest of any joint replacement procedure, with
over 90% reporting a good to excellent overall outcome [2, 3].
Complications related to THA can be classified as either procedure specific or systemic. Ad‐
vances in technology, anaesthesiology and surgical technique have resulted in an overall
temporal decrease in complication rates despite the increasing incidence of co-morbidities in
the patient population [4]. Table 1 highlights rates of complications most commonly encoun‐
tered after THA.
2. Systemic / non-surgical
2.1. Thromboembolic complications
Deep Vein Thrombosis
Distal deep vein thrombosis (DVT) can range from being asymptomatic, to resulting in long
term valvular damage resulting in chronic venous insufficiency. Proximal propagation can
result in more serious pulmonary embolism. The overall incidence of DVT, including both
radiologically diagnosed asymptomatic DVT and symptomatic DVT, post THA in early
studies was reported to be as high as 70% without any form of prophylaxis [15]. Recent sys‐
tematic review of several randomised control trials concerned with DVT prophylaxis has es‐
timated this figure to be around 44% [16]. The recent FOTO study has shown a symptomatic
DVT rate of 1.3% in THA patients with extended duration [36 day) chemical prophylaxis [8].
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The overall combined incidence of asymptomatic and symptomatic DVT with prophylaxis
has not declined with time, converse to the findings with knee arthroplasty in which the in‐
cidence has declined significantly [17]. This may be due to the increasing frequency of co
morbidities within patients undergoing THA which act as risk factors for DVT.
Systemic Procedure Specific
Complication Rate Complication Rate
Subclinical Fat Embolism 90%[5] Dislocation (Posterior
approach with repair)
0.49%[6]
Symptomatic Fat Embolism Unknown Leg length discrepancy
(patient perceived)
30%[7]
Symptomatic Deep Vein
Thrombosis with prophylaxis
1.3%[8] Infection 1.08%[9]
Symptomatic Pulmonary
Embolism with prophylaxis
0.5 – 0.6%[10] Aseptic Loosening 2% failure rate at 15 years
(Corail uncemented stem)
[11]
3.2% failure rate at 30 years
(Exeter Cemented Stem)[12]
Mortality 0.29 – 0.6%[4] Periprosthetic Fracture
(Postoperative femoral)
1.1%[13]
Myocardial Infarction 0.5%[10] Heterotopic Ossification
(Grade III/IV)
3 – 7%[14]
Table 1. Complication rates for Total Hip Arthroplasty
THA is thought to mainly affect 2 limbs of Virchow’s triad, namely hypercoagulability and
venous stasis. Activation of the coagulation cascade begins during surgery, primarily during
preparation and insertion of the femoral prosthesis, with cemented prostheses providing a
greater stimulus than uncemented implants [18]. Whether this increases the incidence of
DVT with cemented fixation is unclear as the evidence is inconclusive [15, 19]. Venous hae‐
modynamics are also altered not only during surgery, but also for up to 6 weeks post opera‐
tively [20]. Significant reductions in venous capacitance and outflow are seen in both legs,
with greater changes seen in the operated leg, and this has been shown to correlate directly
with the incidence of postoperative DVT [20]. Complete femoral vein occlusion has also
been noted during THA, particularly during the posterior approach when the limb is inter‐
nally rotated and flexed for operation on the femur [18].
Numerous risk factors for postoperative DVT have been identified. Major risk factors in ap‐
proximate order of importance include: hip fracture, malignancy, antiphospholipid syn‐
drome, immobility, previous history of DVT, use of selective oestrogen receptor modulators,
oral contraceptives, morbid obesity, stroke, atherosclerosis and a ASA greater than 3 [21].
However 50% of patients who develop DVT have no identifiable clinical risk factor [21]. Ge‐
netic predispositions include antithrombin III and protein C deficiency and prothrombin
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gene mutation [21]. In order to aid recognition of ‘at risk’ patients, the National Institute for
Health and Clinical Excellence (NICE) has published a table of relevant patient related risk
factors as shown in Table 2 [16].
Active cancer or cancer treatment Active heart or respiratory failure
Acute medical illness Age over 60 years
Antiphospholipid syndrome Behcet’s disease
Central venous catheter in situ Continuous travel of more than 3hours approximately
4weeks before or after surgery
Immobility (for example, paralysis or limb in plaster) Inflammatory bowel disease
Myeloproliferative diseases Nephrotic syndrome
Obesity (body mass index > 30kg/m2] Paraproteinaemia
Paroxysmal nocturnal haemoglobinuria Personal or family history of VTE
Pregnancy or puerperium Recent myocardial infarction or stroke
Severe infection Use of oral contraceptives or hormonal replacement therapy
Varicose veins with associated phlebitis
Inherited Thrombophilias for example:
High levels of coagulation factors (for example, Factor
VIII)
Hyperhomocysteinaemia
Low activated protein C resistance (for example, Factor V
Leiden)
Protein C, S and antithrombin deficiencies
Prothrombin 2021A gene mutation
Table 2. Patient related risk factors for Venous Thromboembolism [16]
Prophylaxis against DVT begins with the type of anaesthesia used. Regional compared to
general anaesthesia has been shown to reduce the risk of DVT post THA by over 50% [22,
23]. This is thought to be due to the relative hyperkinetic blood flow seen in the lower limbs
during regional anaesthesia compared to general anaesthesia, and the stabilising effect of lo‐
cal anaesthetics on the cell membranes of vascular endothelium and platelets [24]. Mechani‐
cal and chemical prophylaxis remains a somewhat contentious issue, with various differing
opinions existing regarding prophylaxis regimes. Numerous randomised controlled trials
exist supporting the use of mechanical methods such as pneumatic compression devices
(figure 1) and chemical methods such as low molecular weight heparins and fondaparinux,
a factor Xa inhibitor [25-34].
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Figure 1. Left: Thrombo-Embolic Deterrent Stockings, Right: Flotron pumps (Huntleigh Healthcare Ltd, Luton, UK)
There has been recent increasing interest in oral factor Xa inhibitors such as Rivaroxaban
and Apixaban. The RECORD trial has demonstrated greater effectiveness for oral Rivaroxa‐
ban compared to subcutaneous Enoxaparin with equal side effect profiles [35, 36]. Pooled
analysis of the ADVANCE-2 and ADVANCE-3 trials has also demonstrated greater efficacy
for oral Apixaban compared to subcutaneous Enoxaparin [37]. There has been some recent
concern however regarding the increased rate of wound complications, specifically with the
use of Rivaroxaban [38]. A retrospective analysis by Jensen et al. demonstrated a greater re‐
turn to theatre rate for wound complications such as prolonged drainage and haematoma
associated with the use of Rivaroxaban compared to Tinzaparin [38]. The authors suggest
that trial data to date has not fully evaluated the complications profile of Rivaroxaban, as
only major bleeding was used as a primary outcome measure, and further randomised trials
are necessary to examine rates of surgical complications.
Current recommendations by National Institute for Health and Clinical Excellence (NICE) in
England state that, THA patients should be offered mechanical prophylaxis in the form of
intermittent pneumatic compression devices or compression stockings, and chemical pro‐
phylaxis with either low molecular weight heparin, Fondaparinux, Rivaroxaban or Dabiga‐
tran. This should be continued for 28-35 days post operatively [39].
2.2. Pulmonary embolism
DVTs that propagate proximally have the potential embolise to the lungs resulting in pulmo‐
nary emboli (PE). Mild emboli can be asymptomatic, whereas massive embolism can be fatal,
and PE is one of the leading causes of mortality post THA. Rates for symptomatic pulmonary
embolism in recent large case series of primary THA in which chemical prophylaxis was
used, has been between 0.51-0.6% [10, 40]. In the absence of prophylaxis this is estimated to be
around 3%, with approximately 6% of symptomatic PEs post THA result in fatality [16].
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As with DVT, both mechanical and chemical methods such as pneumatic compression
pumps and low molecular weight heparins have been shown to provide effective prophy‐
laxis against symptomatic PE [25, 41-44]. However due to the low rate of fatal PE, trials and
even meta-analyses have failed to demonstrate statistically significant effects on the rate of
fatal PE by using thromboembolic prophylaxis [45]. Power analysis indicates a trial involv‐
ing 67,000 patients would be needed to demonstrate a statistically significant difference [46].
Vena Caval filters as shown in figure 2 can also be used to prevent migration of venous em‐
boli into the pulmonary circulation. However no RCTs exist supporting their use in surgical
patients and significant complications such as pneumothorax, air embolism and arteriove‐
nous fistulae can develop either during their placement or post procedure [47]. UK NICE
guidelines therefore recommend their use in patients with recent or existing thromboembol‐
ic disease in whom anticoagulation is contraindicated [39].
Figure 2. Retrievable Inferior Vena Caval Filter, courtesy of Cook Medical
2.3. Fat embolism
During insertion of the femoral component, rises in intramedullary pressure can force me‐
dullary fat and marrow contents into the venous circulation via the metaphyseal vessels
[48-50]. Fat and marrow embolus can then pass into and through the pulmonary circulation
depending on the size of the emboli [51, 52]. Large emboli can lodge within the pulmonary
circulation leading to pulmonary hypertension and haemodynamic instability. Trans-pul‐
monary passage of micro-emboli can result in cerebral embolism potentially causing neuro‐
logical complications [51, 53].
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Subclinical fat embolisation can been detected in up to 90% of patients undergoing THA [5].
However the exact incidence of fat embolism syndrome characterised by the classic triad of
respiratory insufficiency, neurolgic symptoms and upper body petechiae is unknown [54].
Measures to reduce the risk of fat embolism include medullary lavage to reduce the fat load
during cement pressurisation [55]. Vacuum cementation techniques using drainage cannu‐
lae have also been shown to be effective in reducing the intramedullary pressure rises dur‐
ing cementation therefore reducing the risk of emboli [56]. Treatment of established fat
embolism syndrome is essentially supportive, frequently requiring intensive care unit ad‐
mission for respiratory support.
3. Mortality and cardiorespiratory complications
Published rates for mortality following primary THA are low, ranging from between 0.29%
to 0.6% [4, 10]. Mortality rates have declined slightly with time despite the increasing inci‐
dence of relevant co-morbidities [4]. Cardiovascular complications account for the most
common cause of death [57].
Age has been identified as one of the strongest predictors of post operative mortality after
joint arthroplasty [10]. Octegenarians have been shown to have a mortality rate 3.4 times
higher than patients between 65-79 years of age and were 2.4 times more likely to suffer a
post operative myocardial infarction [58]. Other significant risk factors for post operative
mortality and morbidity include male sex, smoking and higher American Society of Anes‐
thesiologists’ (ASA) grade which is representative of relevant significant co-morbidities
such  as  artherosclerosis,  diabetes,  renal  impairment  and  valvular  disease  [10,  59,  60].
Greenfield et al. found that the incidence of morbidity after THA varied from 3% to 41%
when comparing those with the lowest and highest incidence of co-morbidities [61]. The
role of anaesthesia is somewhat controversial. Some studies suggest regional compared to
general anaesthesia may reduce the risk of thromboembolic and cardiorespiratory compli‐
cations and short term mortality [62, 63]. Others have shown no difference between the 2
groups in terms of morbidity and mortality [64]. Therefore no conclusive evidence exists
supporting one form of anaesthesia, but the overall consensus would appear to favour re‐
gional techniques [54].
4. Procedure specific / surgical complications
4.1. Dislocation
Dislocation is the 3rd most common cause for revision after THA [65]. Published rates for
dislocation after primary THA vary widely between 0.2% to 7% [66]. Up to 70% of disloca‐
tions occur early within 6 weeks [67]. Early dislocation carries a better prognosis compared
to late dislocation which is defined as occurring after 3 months, as late dislocation usually
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has a multifactiorial aetiology including component wear and soft tissue laxity [68, 69]. Ap‐
proximately a third of dislocating THAs managed conservatively after the first episode will
go on to become recurrent dislocators [67]. Risk factors for dislocation can be classified as
either patient, surgery or implant related.
4.2. Patient related risk factors
Patients with neuromuscular and cognitive disorders such as cerebral palsy, muscular dys‐
trophy and dementia, have been shown to have higher rates of dislocation [70]. Fracture as
the primary indication for surgery is the indication most strongly linked with dislocation
[71]. This is thought to be due to the lack of capsular hypertrophy normally seen with osteo‐
arthritis which provides additional stability. Previous hip surgery of any sort has also been
shown to double the risk of dislocation [68]. Factors such as height, weight, age and sex of
the patient have not been conclusively shown to affect the rates of dislocation [67].
4.3. Surgical risk factors
Surgical factors include surgical approach, soft tissue tension, component design and orien‐
tation, and surgeon experience. The majority of dislocations occur in a posterior direction
and therefore the posterior approach has been deemed to be the approach with the highest
risk of dislocation. Early data supported this theory with Woo et al reporting a rate of 5.8%
for posterior approach compared to 2.3% for an antero-lateral approach [68]. However re‐
cent research investigating the role of posterior capsular and external rotator repair has
shown comparable rates to other approaches [72, 73]. A recent meta-analysis has shown a
reduction of the dislocation rate from 4.46% to 0.49% by carrying out a posterior soft tissue
repair [6]. Therefore with meticulous soft tissue repair, surgical approach should have little
effect on dislocation rates. Besides the posterior structures, the glutei and joint capsule also
provide soft tissue tension reducing dislocation risk. Therefore following a transtrochanteric
approach, trochanteric non union greater than 1cm can result in abductor insufficiency in‐
creasing the rates of dislocation by over 6 fold [68]. Inadequate offset is another factor affect‐
ing soft tissue tension and has been shown to increase dislocation risk [74].
4.4. Implant related factors
Component positioning and design both play key roles in reducing dislocation risk. “Safe
zones” for acetabular cup position are defined as an abduction angle of 40° ± 10° and ante‐
version of 20° ± 10° [75, 76]. With a posterior approach reduced cup anteversion has been
shown to be a major risk factor for dislocation [77]. Archbold et al. have suggested the use of
the transverse acetabular ligament as a landmark to judge cup anteversion [78]. Using this
technique they reported a 0.6% dislocation rate using a posterior approach with soft tissue
repair. How this relates to the traditionally defined safe zones is currently being examined.
Femoral component positioning has been less well studied. Recent studies have suggested
the use of a ‘combined anteversion’ technique in which the acetabular and stem combined
anteversion should be 35° ± 10° [79, 80].
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Femoral head size also affects stability. Larger heads provide more favourable head-neck ra‐
tios, reducing possible impingement, and seat deeper within the acetabulum requiring a
greater ‘jump distance’ to cause dislocation as illustrated in figure 3. Such advantages have
been validated using cadaveric and computer modelling [81-83]. Clinical data from both the
Norwegian and Australian joint registries has also shown a reduction in rates of revision for
dislocation with increasing head size [84, 85].
Surgeon experience is another factor that has been identified in influencing dislocation rates.
Hedlundh et al. found that surgeons who had performed less than 30 THAs had a double
rate of dislocation compared to more experienced surgeons [86]. A recent systematic review
has also demonstrated reduced dislocation rates with increased surgical volume [87].
Figure 3. Jumping Distance highlighted by red arrow demonstrates distance the head needs to travel before disloca‐
tion occurs. Increasing head size increases this distance
5. Management
Management of dislocation initially involves closed reduction which is usually successful in
the majority of cases. This should be performed ideally under anaesthesia with muscle relax‐
ation to reduce the chance of damage to the femoral head [88, 89]. Some surgeons advocate
the use of an abduction brace after reduction but little evidence exists supporting their use.
Indications for operative intervention include recurrent or irreducible dislocation, compo‐
nent malposition, soft tissue laxity and dislocation due to impingement. Strategies during
revision include component realignment, removal of osteophytes causing impingement,
modular component exchange to increase head size and improve head-neck ratio, liner ex‐
change if worn and addressing soft tissue laxity using capsulorrhaphy, trochanteric ad‐
vancement or tendon allografts.
Selected patients unsuitable for major revision surgery can be treated with posterior lip aug‐
mentation devices (PLAD) as shown in figure 4. These consist of a C shaped piece of
UHMWPE and a steel backing plate, and are applied to the posterior lip of the acetabulum
and held in place with up to 5 screws. This constrains the head within the augmented sock‐
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et. Contraindications to its use include gross component malalignment and loosening.
McConway et al. reviewed 307 recurrently dislocating THAs treated with PLADs [90]. Per‐
sistent instability occurred in only 5 patients [1.6%) and there was no evidence of accelerated
loosening affecting the acetabular component.
Salvage procedures for failed revision or uncorrectable aetiology include the use of con‐
strained cups or conversion to bipolar hemiarthroplasty. However both of these procedures
are associated with poor functional outcome and constrained cups can result in premature
loosening [70]. Therefore their use is usually reserved for low demand patients. The final
salvage option is Girdlestone resection for the unreconstructable hip.
Figure 4. Posterior Lip Augementation Device (PLAD, Depuy, UK)
5.1. Leg length discrepancy
Leg length discrepancy (LLD) is the most common cause of patient dissatisfaction and sub‐
sequent litigation after THA [91]. LLD can result in nerve palsies, abnormal gait, lower back
pain and reduced functional outcome [92]. Wylde et al. showed up to 30% of patients after
primary THA can have a perceived LLD, but only 36% of these had an anatomic LLD great‐
er than 5mm [7].
Nerve palsies are potentially the most serious complications of LLD. Sciatic and peroneal
nerve palsies have both been associated with limb lengthening. Edwards et al suggested sci‐
atic and peroneal nerve palsies are associated with lengthening greater than 4 and 3.8cm re‐
spectively [93]. Farrell et al however found an average lengthening of only 1.7cm was a
significant risk factor for nerve palsies [94]. Therefore safe limits for limb lengthening before
traction nerve palsies develop are yet to be defined, and it may be that any minor degree of
lengthening may make the nerve more susceptible to other trauma [94].
Minor LLD less than 1cm is usually well tolerated by patients. However LLD greater than
2cm has been shown to significantly affect the gait cycle, increasing physiological demand
[95]. LLD greater than 3cm in the elderly was shown to cause significant increases in heart
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rate and quadriceps activity in the lengthened limb, which may be especially relevant in pa‐
tients with cardio-respiratory co-morbidities [95].
Avoiding potential problems with LLD begins with patient history and examination. It is
crucial to determine patient perceived leg length in order to counsel the patient effectively
regarding likely outcomes. True leg length can then be determined, measuring from the ipsi‐
lateral anterior superior iliac spine to the medial malleolus, followed by apparent leg length
by measuring from the umbilicus to the medial malleolus. Apparent leg length can be affect‐
ed by pelvic obliquity secondary to either lumbar spine pathology or contractures about the
hip. Significant LLD due to fixed pelvic obliquity secondary to chronic lumbar spine pathol‐
ogy cannot usually be corrected as it may involve significant shortening or lengthening.
With pelvic obliquity secondary to contractures, the true length only needs to be corrected
as after the THA the pelvis will balance with time [96].
Radiographs can also be used to determine leg length by referencing the position of the less‐
er trochanter in relation to a line drawn across the inferior aspect of the pelvis as shown in
figure 5. Templating can then be carried out to determine the correct level of the neck cut for
the femoral prosthesis and the position of the acetabular component in order to determine
the new hip centre. Both of these directly affect leg length.
Figure 5. Radiographic estimation of LLD can be made by measuring vertically from the top of the lesser trochanter to
a line drawn across the inferior margin of the pelvis
Intraoperative methods include the use of measurements taken from reference pins placed
in the pelvis to a mark on the greater trochanter [97-99]. Mihalko et al described using a
large fragment screw placed above the superior rim of the acetabulum and marking a point
on the greater trochanter a fixed distance from this prior to dislocation. After insertion of the
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prostheses this distance was rechecked giving an indication of leg length changes [98]. Shir‐
amizu et al used a similar method but with a steimann pin in the ilium and a custom calliper
to measure the distances [99]. They found a mean LLD of only 2.1mm with this method.
Minor LLD postoperatively can be treated using a shoe raise. Prescription of such devices
should be delayed for 3-6 months to allow any residual pelvic tilt secondary to contractures
to resolve as the soft tissues can progressively relax. Failure of conservative measures and
symptoms such as severe pain, nerve palsies and instability can necessitate surgical inter‐
vention. Shortening can be treated using soft tissue release and exchange of modular heads
to give modest changes in leg length or more extensive surgery such as exchange of the fem‐
oral component to give greater neck length or offset. Lengthening can also be treated with
component exchange but secondary procedures such as trochanteric advancement or the use
of larger heads or stems with increased offset may be needed to maintain stability [100].
5.2. Infection
Infection post THA is potentially one of the most catastrophic and challenging to treat com‐
plications. During the early development of THA, Charnley reported a deep infection rate of
9.4% in unventilated operating theatres [101]. This initial unacceptably high deep infection
rate stimulated the development of several prophylactic measures including ultraclean lami‐
nar air flow ventilation and peri-operative antibiotics. With the aid of such measures, infec‐
tion rates in the UK between 1993 and 1996 fell to 1.08% [9].
5.3. Prophylaxis
Bacterial contamination of theatre air was initially recognized as a risk factor for post opera‐
tive sepsis by Lister in 1867 [102]. Charnley later introduced the concept of ultraclean air
flow ventilation that produces less than 10 colony forming units per cubic meter [103]. His
reported infection rates in THA fell to 1% with the use of such enclosures. A MRC trial pub‐
lished in 1982 demonstrated a deep sepsis rate of 0.6% with ultraclean ventilation compared
to 1.5% with conventional ventilation [104]. The use of ultraclean air ventilation during joint
arthroplasty has subsequently become universally adopted practice within the UK [105].
The use of peri-operative antibiotics during THA is also a common prophylactic measure.
Early trials using cloxacillin in THA found a 12% infection rate without prophylaxis com‐
pared to 0% with [106]. Currently cephalosporins are commonly used prophylaxis for THA.
There is however a gradual move away from these due to the emergence of MRSA and
problems with Clostridium difficile infection. Alternative regimens include flucloxacillin
and gentamicin, or vancomycin and gentamicin. There is no conclusive evidence with re‐
gards to the optimal antibiotic regimen or duration of administration. However no benefit of
extended prophylaxis beyond 24 hours has been demonstrated [107]. Therefore antibiotic re‐
gimes should be ideally guided by local microbiological knowledge so locally prevalent or‐
ganisms can be targeted. Other measures shown to reduce rates of infection or bacterial load
include the use of occlusive clothing, exhaust suits, pulsed wound lavage, preoperative
showering and reducing theatre traffic [105].
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5.4. Pathogenesis
Infection can arise by direct bacterial contamination at the time of surgery or later haema‐
togenous spread. Staphylococcus aureus was the most common causative organism in an
early series published by Charnley [108]. Coagulase negative staphylococci have become in‐
creasingly prevalent over the years with a recent series showing such organisms responsible
for 58% of infections [109]. This is thought to be due to the effect of antibiotic use on bacteri‐
al flora [105]. Risk factors for periprosthetic infection include obesity, revision surgery, in‐
flammatory arthritis, open skin lesions on the affected limb, blood transfusion, urinary
infections and high ASA score [110].
Pathogenesis begins with bacterial adhesion. Primary adhesion occurs due to physical inter‐
actions (hydrophobic/electrostatic) between the bacteria and prosthetic surface. This is fol‐
lowed by bacterial aggregation through membrane adhesion molecules and generation of
exopolysaccharides which form a glyocalyx or biofilm surrounding the bacteria [111]. This
biofilm is thought to protect the bacteria from antibiotics and host defences [112].
5.5. Classification
Periprosthetic infections can be classified into 4 main catogeries [113]. Early postoperative
infection is one that becomes apparent within one month of the procedure. Late chronic in‐
fection presents later than 1 month after operation and has an insidious course of gradual
onset of pain and swelling with minimal systemic symptoms. Acute haematogenous spread
results in an acute onset of symptoms associated with a documented or suspected bacterae‐
mia. The final type is positive intra-operative culture, this is an occult infection diagnosed
by positive cultures taken at time of revision surgery.
5.6. Diagnosis
Diagnosis of peri-prosthetic infection can be extremely challenging. Hip pain is the most
consistent symptom. Presence of systemic symptoms such as fevers or rigors can be very
variable. Examination may reveal local wound tenderness, signs of inflammation, discharge,
sinuses and a painful range of movement.
Plain radiographs may show evidence of osteopenia or osteolysis, periostiitis and endosteal
scalloping. However none of these can reliably differentiate between infection and aseptic
loosening. Radionucleotide scanning using technetium or gallium can also been used. Tech‐
netium uptake reflects active bone turnover and gallium binds to transferrin, accumulating
in inflammatory foci. Technetium scanning has a greater sensitivity than gallium for infec‐
tion but their inability to differentiate infection and aseptic loosening limits their application
[114, 115]. However its relatively high negative predictive value can make technetium bone
scanning a useful initial screening test [116]. 18F-Fluoro-deoxyglucose [18-FDG) PET scan‐
ning is a newer technique that has increased sensitivity and specificity for infection. Pooled
data from recent studies demonstrate a sensitivity of 85.5% and a specificity of 92.6% for
periprosthetic infection [117]. Availability of PET scanners however still remains poor. Us‐
ing radio-labelled white cells or immunoglobulins is another technique which has shown
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improved sensitivity and specificity relative to traditional three phase bone scans. Their
widespread availability combined with the lack of established diagnostic criteria for 18-FDG
PET scans, makes labelled white cell scans the current nuclear medicine investigation of
choice for periprosthetic infection [118].
Blood investigations include ESR, CRP and Interleukin-6. ESR and CRP are non specific in‐
flammatory markers and therefore can be elevated by concurrent illnesses. In the absence of
such conditions an ESR greater than 30 mm/hr has a sensitivity and specificity of 82 and 85%
respectively for peri-prosthetic infection, and the values for a CRP greater than 10mg/l are
96% and 92% [119]. Elevated levels of interleukin-6 have also been associated with peripros‐
thetic infection with a sensitivity and specificity of 100% and 95% in one study [120]. How‐
ever other chronic inflammatory conditions such as rheumatoid arthritis and other illnesses
such as AIDS and Multiple Sclerosis can also cause elevated levels.
Cytological and microbiological analysis of hip aspirate taken under sterile conditions can
give useful information regarding not only the presence of infection but also the potential
offending organism. Ali et al. have shown a sensitivity and specificity of 0.82 and 0.91 for
radiologically guided guided hip aspiration. However recent antibiotics can affect cultures
and therefore antibiotics must be stopped for at least 2 weeks prior to aspiration.
5.7. Treatment
The aims of treatment of an infected prosthesis are eradication of infection and restoration of
function. The classification by Tsukyama et al. can be used to help guide treatment [113].
Acute infections either presenting as early infection or acute haematogenous spread can be
treated by component retention and thorough debridement, irrigation and intravenous anti‐
biotics. However such treatment must be undertaken within 2 weeks of onset of symptoms
[121]. Success rates between 50-74% have been reported with such a strategy [113].
Late chronic infection is best treated with full revision. This can be performed as a single
stage exchange arthroplasty or a 2 stage exchange procedure. Originally described by Bu‐
cholz, a single stage procedure involves prosthesis removal, soft tissue debridement and
lavage, followed by re-implantation of a new prosthesis if a clean uninfected bed is ach‐
ieved, followed by appropriate antibiotic therapy [122]. Review of 1299 cases treated with
single stage revision showed an 83% success rate at an average follow up of 4.8 years [123].
Factors associated with successful outcome were good general health of the patient, absence
of wound complications after the primary procedure, methicillin sensitive organisms and in‐
fection with organisms sensitive to antibiotics within the cement [123]. Advantages of a sin‐
gle stage procedure include lower patient morbidity and lower incidence of complications
such as fracture and dislocation. However 2 stage procedures have consistently demonstrat‐
ed higher success rates compared to single stage procedures [124-128]. Thus 2 stage ex‐
change still remains the most common strategy.
2 stage procedures involve initial prosthesis removal, soft tissue debridement and insertion
of an antibiotic loaded cement spacer. This can be in the form of an articulating spacer al‐
lowing some range of movement and reducing soft tissue contracture. This is followed by
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appropriate antibiotic therapy and a usual interval of 6 weeks prior to reimplantation of the
definite new prosthesis. Success rates of between 87 to 94% have been reported with cement‐
ed 2 stage revision [124, 125, 128].
6. Nerve and vessel injury
The overall incidence of nerve injury after THA is estimated to be around 1% [129]. Sciatic
nerve palsies account for 79% of all cases, followed by femoral nerve palsies (13%), com‐
bined femoral and sciatic nerve palsy (5.8%) and obturator nerve palsy (1.6%) [129]. In the
majority of cases (47%) the aetiology is unknown. Other causes include traction (20%), con‐
tusion (19%), haematoma (11%) and dislocation (2%), with laceration only accounting for 1%
of all nerve palsies [130]. Risk factors for nerve injury include female sex, revision surgery
and developmental dysplasia of the acetabulum [129].
When the sciatic nerve is affected, it most commonly involves the common peroneal divi‐
sion. This is thought to be due to the lower amount of connective tissue present between the
funiculi and its relatively tethered position at the sciatic notch compared to the tibial branch
[129, 131]. These factors are thought to make the peroneal branch more susceptible to trau‐
ma and traction. The use of the posterior approach has traditionally been associated with in‐
creased risk of sciatic nerve damage. However a Cochrane review in 2006 found no
difference in the incidence of nerve palsy between the posterior and direct lateral ap‐
proaches [132]. Femoral nerve palsy is less common and is usually secondary to direct com‐
pression, usually due to a malpositioned retractor [130].
Indications for surgical intervention in a patient with nerve palsy include haematoma caus‐
ing compression, palsy associated with excessive lengthening and palsy that can be definite‐
ly attributed to implanted metalwork. Electrodiagnostic studies can be helpful in
determining the level of the lesion. Outcomes of nerve palsies are variable, with 40% of pa‐
tients showing a good recovery, 45% of patients having mild residual motor or sensory
symptoms and 15% left with a dense motor or sensory deficit [129]. Partial nerve lesions and
maintenance of some motor function are good prognostic indicators, with recovery possible
for up to 3 years after the initial insult [133].
Vascular injury during THA is extremely rare. Published incidence varies between 0.04 to
0.08% [134, 135]. As opposed to knee arthroplasty, vascular injury in THA is usually the re‐
sult of direct trauma either during component insertion or removal [136]. Risk factors in‐
clude revision surgery, previous vascular injury or surgery and pre-existing atherosclerosis
[137]. The majority of vascular injuries are arterial but venous injury has been described
[138]. Venous injuries however may be under diagnosed as they may run a relatively benign
course remaining undetected.
The majority of vascular injuries are either the result direct trauma from acetabular retrac‐
tors or acetabular screw insertion [130]. Wasielewski et al. have described an acetabular
quadrant system to help guide safe screw insertion [139]. The postero-superior and poster-
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inferior quadrants are the safest zones for screw insertion as they have they areas of greatest
bone stock [139].
6.1. Wear and aseptic loosening
Aseptic loosening is the most common cause for revision surgery, accounting for 75% of re‐
vision cases [140]. Aseptic failure occurs as a result of a chronic inflammatory reaction sec‐
ondary to particulate wear debris eventually resulting in osteoclast activation, osteolysis
and loosening [141].
The pathogenesis begins with the generation of wear particles from the bearing surface, and
also non bearing surfaces such as the interface between acetabular shell and the liner insert,
known as backside wear. The morphology of the wear debris is dependent on the type of
implant used. Particles from polyethylene bearing surfaces can vary from submicron in size
to several millimetres. The average size of polyethylene debris has been shown to be around
0.5 µm and it is this submicron sized particle that has been shown to have the most bio-reac‐
tivity [142, 143]. The rate of generation of the wear particles has also been shown to correlate
with the degree of osteolysis [142]. Inadequate initial fixation can also contribute to loosen‐
ing by generating micromotion and increasing the rate of generation of particulate debris
[144]. This highlights the importance of good cementation techniques in reducing the risk of
aseptic failure. Pressure within the joint fluid has also been suggested to contribute to os‐
teolysis. Increased joint fluid pressure in animal models has been shown to induce bone loss
at the prosthesis bone interface possibly by interfering with bone perfusion causing osteo‐
cyte death [145, 146]. Increased joint fluid pressures have been noted in THAs undergoing
revision and pressure waves generated by load bearing have been demonstrated in retroace‐
tabular lytic lesions [147, 148]. Thus increased fluid pressures may directly contribute to os‐
teolysis and also perpetuate the dissemination of the wear debris throughout the prosthesis
bone interface, enhancing the biological response.
The primary response to wear debris is predominantly macrophage mediated. The exact
mechanism of macrophage activation is still unclear. Macrophages can be activated as a re‐
sult of either phagocytosis of particulate matter and also possibly through cell membrane in‐
teractions with particulate matter [149]. Macrophage activation causes the release of pro-
inflammatory cytokines and growth factors including TNF-α, Interleukin-1, TGF-β and
RANKL [150]. This results in the production of a pseudomembrane at the bone cement pros‐
thesis interface consisting of macrophages, fibroblasts and lymphocytes within a connective
tissue matrix [151]. TNF-α and Interleukin-1 both promote osteoclastic differentiation and
activation, but it is the up regulation of the RANK/RANKL pathway that is the key to acti‐
vating osteoclastogenesis and subsequent osteolysis [143]. Recent studies have suggested in‐
dividual genetic susceptibility to osteolysis may exist via single nucleotide polymorphisms
in the implicated cytokine genes, possibly by altering the magnitude of the biological re‐
sponse [152-155].
Alternative bearing surfaces can be used to reduce wear rates, debris generation and subse‐
quent osteolysis. Highly crosslinked polyethylene, ceramic on ceramic and metal on metal
bearings have all been shown to have reduced wear rates compared to standard ultra-high
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molecular weight polyethylene (UHWPE) [156-164]. However there are concerns regarding
the increased bioreactivity of crosslinked polyethylene debris compared to standard
UHWPE which may offset the benefits of reduced volumetric wear [165, 166]. Volumetric
wear is also lower with metal on metal bearings. However as the particle size is much small‐
er, usually between 20-90nm, the overall surface area is much larger compared to UHWPE
raising concerns of possible increased bioreactivity.
Pain is usually the primary presenting symptom of aseptic failure. Gross acetabular loosen‐
ing can cause groin pain whereas thigh pain can indicate femoral loosening [167]. Early loos‐
ening however may also be asymptomatic merely detected on routine follow up
radiographs. Clinical signs may include inability to straight leg raise, shortening of the leg
due to subsidence and increasing external rotation of the leg if the femoral stem twists into
retroversion. Investigations for aseptic loosening are similar to those for infection discussed
earlier. Blood inflammatory markers such as CRP are usually normal with aseptic loosening
[168]. Radiological tests include plain radiography, subtraction and nuclear arthrography
and bone scintigraphy. Meta-analysis has shown similar diagnostic performance for all of
these tests and therefore suggests plain radiographs and bone scintigraphy as the tests of
choice due to their lower risk of patient morbidity [169]. CT 3D imaging is also useful for the
evaluation of lytic lesions as plain 2 dimensional radiographs can underestimate the size of
the lesion as demonstrated in figure 1 [170, 171].
Figure 6. Top left & right, Progressive acetabular osteolysis over 1.5 years, Bottom left, 3D CT reconstruction demon‐
strating lesion and pelvic discontinuity, Bottom right, defect reconstructed with mesh and bone graft and plate to
posterior column to address discontinuity
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Treatment of aseptic loosening is guided by the severity of the patient’s symptoms and the
rate and volume of osteolysis. Indications for surgical treatment in asymptomatic patients
are progressive osteolysis and risk of catastrophic mechanical failure such as periprosthetic
fracture. Nonsurgical treatment using bisphosphonates and anti cytokine therapy such as
anti-TNF-α to prevent progression of osteolysis has been suggested. However their efficacy
is yet to be determined [172]. Goals of surgical treatment include removal of wear debris
and also the wear generator, reconstruction of the osseous lesion and restoration of mechan‐
ical stability [173]. This can involve exchange of bearing surfaces, bone grafting of lytic le‐
sions and revision of loose components.
7. Bearing specific complications
7.1. Ceramic on ceramic bearings
Ceramic articulations have become increasingly popular due to their low wear profile and
good biocompatibility. However potential complications of ceramic bearings include chip‐
ping and incomplete seating of ceramic liners during insertion, fracture and bearing gener‐
ated noise.
Currently all ceramic acetabular bearings consist of a modular ceramic liner which is insert‐
ed into a metal shell implanted into the acetabulum. Incomplete seating of the liner due to
soft tissue interposition or deformation of the metal shell has been reported [174, 175]. Thus
extra care and good visualisation of the acetabulum is imperative when inserting a modular
ceramic liner. Chipping during impaction has also been reported and this can also be secon‐
dary to deformation of the metal shell [176]. Using titanium sleeved or recessed ceramic lin‐
ers has been shown to reduce such risks [177].
Risk of fracture for modern 3rd generation ceramic bearings is extremely low. Willman et al.
found a fracture rate of 0.004% for femoral heads manufactured after 1994 [178]. Fracture of
both the liner and femoral head have however been reported [179, 180]. Head fracture has
been associated with improper handling during implantation. Contamination of the stem-
ball interface with blood or soft tissue has been shown to significantly reduce the load re‐
quired for inducing fracture [181]. Impingement of the femoral neck on the edge of ceramics
liner is thought to be a major risk factor for liner fracture [179, 182]. Therefore correct posi‐
tioning of the acetabular component is especially important for ceramic bearings.
Noise generated from ceramic bearings is a recently described phenomenon. Published rates
of “squeaky” ceramic bearings range from 2.7% to 20.9% [183, 184]. Component malposition
has been implicated [185]. However recent studies have found no association between cup
inclination and version and the incidence of squeaking [183, 184]. Short neck length is the
only factor that has been associated with squeaking, possibly due to impingement or micro‐
seperation to due increased joint laxity [184]. Revision of squeaking hips has revealed evi‐
dence of stripe wear but there is currently no evidence to suggest squeaking is a precursor
for ceramic fracture [186, 187].
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7.2. Metal on metal bearings
Metal on metal bearings also have superior wear rates compared to standard UHMWPE
[161, 163, 164]. However there is increasing concern regarding metal ion toxicity and hyper‐
sensitivity type reactions. Volumetric wear is considerably lower for metal bearings com‐
pared to UHMWPE, but the absolute number of particles generated is estimated to be 13500
times higher [188]. Therefore the total surface area is considerably higher. Thus the bioreac‐
tivity of metal wear particles may be higher than polyethylene or ceramic debris, and the
nanometre scale of the particles and dissolution of metal ions allows distant transport, rais‐
ing concerns of systemic toxicity.
The possibility of systemic toxicity has raised interest in serum metal ion levels in patients with
modern metal on metal bearings. Recent studies using standardised measurement techniques
have reported mean serum chromium levels of between 0.86 – 17.7 µg/L [189-192]. Safe levels
of serum metal ion levels have however yet to be determined [193]. Concerns regarding carci‐
nogenesis and immune suppression secondary to raised blood metal ion levels have been
raised [194, 195]. Teratogenicity is also another potential concern as transplacental crossage of
metal ions has been demonstrated [196]. However, currently no conclusive evidence exists
supporting these theories [197, 198]. A positive correlation between cup inclination and blood
metal ion levels has been demonstrated with metal on metal bearings [191, 199]. This is proba‐
bly due to increased edge loading with increasing cup inclination and serum metal ion levels
have been suggested as a tool to monitor the performance of metal on metal bearings [190].
Therefore metal ion exposure can be minimised with proper cup orientation.
Local tissue reactions to metal on metal articulations have also been reported [200-202]. Met‐
al ions are thought to induce an immune reaction leading to tissue necrosis and osteolysis.
This is in contrast to UHMWPE which induces a macrophage reaction to particulate wear
debris. Willert et al. has called this unique reaction, aseptic lymphocytic vasculitic associated
lesions (ALVAL) [200]. Histologically this reaction is characterised by perivascular lympho‐
cytic infiltration and plasma cells. Clinical presentation can vary between chronic groin pain
to extensive tissue necrosis forming pseudotumours [201]. Exact incidence of such tissue re‐
actions is unknown but is estimated to be around 1% [201]. Risk factors associated with the
development of these adverse reactions include small component size and component mal‐
position [203]. Stemmed metal on metal hip replacements also appear to have a higher rate
of revision and their use has now been discouraged [204].
8. Periprosthetic fracture
Periprosthetic fractures can occur either intraoperatively or in the postoperative period. Over‐
all, periprosthetic fractures more commonly affect the femoral component of the THA. Data
from the largest published series by Berry et al. reports the incidence of intra- and postopera‐
tive femoral fracture as 1% and 1.1% respectively [13]. Rates of intraoperative fracture after ce‐
mentless fixation are higher, 5.4% for primary THAs and 21% for revision surgery [13].
Arthroplasty - Update398
The treatment of unstable postoperative periprosthetic femoral fractures is now almost al‐
ways operative. Loosening, non-union, varus malunion and morbidity associated with pro‐
longed immobility have made conservative management unpopular [205]. Treatment can be
guided by using the Vancouver classification which is the most widely accepted system for
classifying such fractures [206]. This system takes into account three main factors, site of the
fracture, stability of the implant and quality of the surrounding bone. Type A fractures oc‐
cur in the trochanteric region and are subdivided into type AG and AL fractures. AG fractures
involve the greater trochanter and usually stable and can therefore be treated conservatively
with protected weightbearing. AL fractures involve the lesser trochanter, and are also usual‐
ly insignificant unless a large portion of the calcar is involved potentially affecting implant
stability, in which case revision THA may be necessary. Type B fractures occur around or
just distal to the stem and are subdivided into type B1, B2 and B3 fractures. B1 fractures have
a well fixed stem and can be treated with open reduction and internal fixation. Combined
plate and cerclage wire systems are commonly used for such fractures. Type B2 fractures
have a loose stem but good bone stock. These are usually revised with long stem implants
bypassing the fracture, and can be augmented by plates, cables and strut allografts to im‐
prove stability. Type B3 fractures have a loose stem and poor stock stock. These are the most
difficult to treat and require either revision THA with structural allografts to reconstitute the
proximal femur, distally fixed long stemmed implants of custom proximal femoral replace‐
ment. Type C fractures occur distal to the stem. The stem can therefore essentially be ignor‐
ed and the fracture treated with standard open reduction and internal fixation.
Acetabular fractures are somewhat less common with reported intraoperative rates ranging
between 0.02-0.4% [207, 208]. Data regarding postoperative fractures is currently not availa‐
ble [13]. The majority of intraoperative acetabular fractures occur during acetabular inser‐
tion especially during impaction of pressfit cementless components [209]. Underreaming by
greater than 2mm has been suggested to significantly increase fracture risk [210].
The aims of treatment of intraoperative acetabular fractures include stabilizing the fracture
and preventing further propagation and maintaining component stability [209]. Techniques
include plating the anterior and posterior columns and using bone graft and jumbo revision
cups if there is marked bone loss. Treatment of postoperative fractures follows similar prin‐
ciples. Early postoperative fractures with stable cups and minimally displaced fractures, es‐
pecially around uncemented implants with supplemental screw fixation, can be treated
conservatively. Unstable cups require revision with fixation of the fracture. Late presenting
fractures are frequently associated with osteolysis and therefore usually require revision
with bone grafting [211].
9. Heterotopic ossification
Heterotopic ossification (HO) is the abnormal formation of mature lamellar bone within ex‐
traskeletal soft tissues. HO is most commonly asymptomatic, merely detected on follow up
radiology. When symptomatic, stiffness is the most common presentation. Pain and soft tis‐
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sue signs such as localised warmth, mild oedema and erythema are uncommon but can
cause confusion raising concerns over infection [212].
Early changes of HO within the soft tissues can be detected after 3 weeks on bone scan and
plain radiographic changes can take 6 weeks to become apparent [212]. Extensive bone dep‐
osition can occur within 3 months, but full maturation takes up to one year [213]. The abduc‐
tor compartment is most commonly affected. HO is most commonly classified using the
Brooker classification [214]. This is based upon plain anteroposterior radiographs of the pel‐
vis and is outlined in figure 7.
Figure 7. Brooker classification showing a) grade 1: islands of bone within the soft tissues about the hip, b) grade 2:
bony spurs from either the femur or the pelvis, with a gap of more than 1 cm between opposing bony ends, c) grade
3: the gaps between the spurs are less than 1 cm and d) grade 4: apparent ankylosis of the hip due to the heterotopic
ossification.
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The pathophysiology is believed to involve inappropriate differentiation of pluripotent mes‐
enchymal stem cells into osteoblasts, causing the excess bone formation [215]. Overexpres‐
sion of bone morphogenetic protein-4 has been implicated [216, 217].
Incidence of clinically significant HO is reported to be between 3 – 7% [218, 219]. Risk factors
include male gender, previous history of HO, pre-existing hip fusion, hypertrophic osteoar‐
thritis, ankylosing spondylitis, diffuse idiopathic skeletal hyperostosis, Paget’s disease, post
traumatic osteoarthritis, osteonecrosis and rheumatoid arthritis [14]. Surgical factors include
extensive soft tissue dissection, haematoma and persistence of bone debris. Evidence impli‐
cating the role of surgical approach is debatable [14].
Treatment of symptomatic patients can initially involve intensive physiotherapy during the
maturation phase. The efficacy of this treatment is however yet to be determined. Surgical
management involves excision of the HO after maturation of the bone is allowed, followed
by appropriate prophylaxis. Improvements in range of motion in all planes has been report‐
ed with surgical excision [220].
Patients at high risk of HO should be given prophylaxis either in the form of non steroidal
anti-inflammatory medication (NSAIDs) or radiotherapy. Preoperative radiotherapy, 4
hours before, or post operative radiotherapy within 72 hours has been shown to be the most
effective method of prophylaxis [221-223]. This involves a single dose of between 7 – 8 Gy.
Combination therapy with NSAIDs and radiotherapy can be considered in patients at high‐
est risk of HO such as patients undergoing excision of symptomatic HO [14].
10. Conclusion
• Complications following total hip arthroplasty can be classified into procedure specific or
systemic. On the whole complication rates have fallen with time due to improved surgical
and anaesthetic technique.
• The most common symptomatic systemic complication is DVT and data suggests that
DVT rates post THA have not fallen with time.
• The most common cause for revision is aseptic loosening. Registry data suggests up to
75% of revision surgery may be due to aseptic loosening.
• Infection is one of the most feared complications. Rates with prophylactic measures such
as antibiotics and clean air enclosures have however dropped significantly to below 1%.
• Leg length discrepancy is one of the most common causes of patient dissatisfaction and is
the most common cause of litigation in the USA.
Despite the potential wide range of complication that can occur after THA, it remains one of
the most successful orthopaedic interventions
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